See today's BioWorld
To read the full story, subscribe or sign in.

Paradigm's AU$16M moves Zilosul to pivotal osteoarthritis trials

Dec. 9, 2024
By Tamra Sami
Paradigm Biopharmaceuticals Ltd. raised AU$16 million (US$10.31 million) in a placement that will allow the company to start a global phase III trial with its lead product, Zilosul (injectable pentosan polysulfate/iPPS), to treat osteoarthritis.
BioWorld Clinical Financings Inflammatory Musculoskeletal Mezzanine Asia-Pacific Australia FDA